https://www.marketscreener.com/quote/stock/PFIZER-INC-23365019/news/Pfizer-Announces-Topline-Phase-2b-Results-of-Oral-GLP-1R-Agonist-Danuglipron-in-Adults-with-Obesit-45482404/?utm_source=telegram&utm_medium=social&utm_campaign=share